Rhythm Pharmaceuticals is preparing for a Q3 filing for cetmelanotide in acquired hypothalamic obesity (HO), following positive Phase III trial results. The company anticipates non-GAAP operating expenses between $285 million and $315 million. Future guidance projects continued growth, with revenue forecasts reaching $183.41 million for FY2025 and $290.95 million for FY2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.